Skip to main content

Table 1 Possible risk factors for invasive fungal diseases (IFD, n = 28) and invasive aspergillosis (n = 18)

From: Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study

 

Univariate analysis for IFDs

Univariate analysis for Aspergillosis

Risk factors

No. of patientsa

IFD

OR

95 % CI

p-value

No. of patientsa

Aspergillus

OR

95 % CI

p-value

n

%

n

%

Gender

            

 male

130

10

7.7

   

126

6

4.8

   

 female

112

18

16.1

2.3

1.01–5.2

0.05

106

12

11.3

2.6

0.9–7.1

0.07

Underlying disease

            

 leukemia

189

22

11.6

1.0

0.4–2.7

0.9

179

12

6.7

0.6

0.2–1.6

0.3

 lymphoma

27

5

18.5

1.9

0.7–5.5

0.2

27

5

18.5

3.4

1.1–10.3

0.03

 others

26

1

3.8

-

-

-

26

1

3.8

-

-

-

Graft type

            

 PBSC

211

25

11.8

1.3

0.4–4.4

0.7

201

15

7.5

0.8

0.2–2.8

0.7

 cord blood

22

3

13.6

1.2

0.3–4.5

0.8

22

3

13.6

2.1

0.5–7.7

0.3

 bone marrow

9

0

0

-

-

-

9

0

0

-

-

-

Donor type

            

 unrelated

177

21

11.9

   

172

16

9

   

 related

65

7

10.8

0.9

0.4–2.2

0.8

60

2

3

0.3

0.1–1.5

0.2

HLA-matched donor

            

 matched

194

22

11.3

   

184

12

6.2

   

 mismatched

48

6

12.5

1.1

0.4–2.9

0.8

48

6

12.5

2.1

0.7–5.8

0.2

Conditioning regimen

            

 reduced-intensity

143

17

11.9

   

137

11

8

   

 myeloablative

99

11

11.1

0.9

0.4–2.1

0.9

95

7

7.4

0.9

0.3–2.4

0.9

EBMT score

            

 EBMT ≤ 2

69

13

18.8

   

64

8

12.5

   

 EBMT > 2

173

15

8.7

0.4

0.2–0.9

0.03

168

10

6

0.4

0.2–1.2

0.1

acute GvHD

            

 no GvHD or I-II°

167

18

10.8

   

158

9

5.7

   

 severe GvHD

75

10

13.3

1.3

0.6–2.9

0.6

74

9

12.2

2.3

0.9–6

0.09

chronic GvHD

            

 no GvHD or I-II°

188

22

11.7

   

181

15

8.3

   

 severe GvHD

54

6

11.1

0.9

0.4–2.5

0.9

51

3

5.9

0.7

0.2–2.5

0.6

Intensified GvHD therapyb

            

 no

215

19

8.8

   

206

10

4.9

   

 yes

27

9

33.3

5.2

2–13.1

0.001

26

8

30.8

8.7

3.1–24.8

<0.001

CMV reactivation

            

 no

154

15

9.7

   

147

8

5.4

   

 yes

88

13

14.8

1.6

0.7–3.6

0.2

85

10

11.8

2.3

0.9–6.1

0.09

TMA

            

 no

225

22

9.8

   

215

12

5.6

   

 yes

17

6

35.3

5

1.7–14.9

0.004

17

6

35.3

9.2

2.9–29.2

<0.001

St.p. IFD

            

 no

213

25

11.7

   

204

16

7.8

   

 yes

29

3

10.3

0.9

0.3–3.1

0.8

28

2

7.1

0.9

0.2–4.2

0.9

Antifungal prophylaxisc

            

 no

160

24

15

   

152

16

10

   

 yes

82

4

4.9

0.3

0.1–0.9

0.03

80

2

2.5

0.2

0.1–0.97

0.05

  1. anumber of patients: n = 242 for all IFDs and n = 232 for aspergillosis excluding all other IFDs
  2. bIntensified GvHD therapy: high-dose glucocorticoid (≥1 mg/kg body weight) and either etanercept or basiliximab
  3. cAntifungal prophylaxis: systemic prophylaxis during aplasia and during post-engraftment
  4. Abbreviations: OR odds ratio, CI confidence interval, PBSC peripheral blood stem cells, HLA human leukocyte antigen, EBMT European Society of Blood and Marrow Transplantation, GvHD graft-versus-host disease, CMV cytomegalovirus, TMA transplant-associated microangiopathy
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us